An interventional study of Alfuzosin GITS (Xatral XL) in Prostatic Hyperplasia, Urinary Retention and Acute Disease, sponsored by Hospital Authority, Hong Kong. Terminated at 1 site in China. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-06-16.
Sponsored by Hospital Authority, Hong Kong · Not applicable, Interventional, and Treatment
The purpose of the study is to compare alfuzosin GITS once daily versus placebo in achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or avoiding a TURP.
803 studies on the registry are indexed under Prostatic Hyperplasia; 174 are open to participants now.
This study's planned enrollment of 48 is below the median of 96 across 610 interventional studies indexed under Prostatic Hyperplasia.
Browse Prostatic Hyperplasia studies →Hospital Authority, Hong Kong is the lead sponsor of 79 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Successful rate of Trial Without Catheter (TWOC) at phase 1
Time frame: At discharge after TWOC (at the end phase one)
Late failure of TWOC of, which is defined as recurrent of AUR or the need of invasive therapy among those who are successful in TWOC in phase 1
Time frame: From the end of phase one to eight months after successful TWOC (the end of phase 2)
Proportion of subjects with hypotension or symptoms related to hypotension after administration of treatment drug for TWOC
Time frame: From the time of treatment drug administration to the end of phase 1
Peak flow rate (Qmax), voided volume (Vcomp) and post-voided residue volume (PVR)
Time frame: At the end of phase I (discharge after TWOC) and at the end of phase 2
This study is terminated, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Authority, Hong Kong